Industry news

New lasers to fight cancers and analyze gases under way in Russia

Marchmont Innovation News

Rostec, Russia’s largest government-owned umbrella corporation for technology development, is developing new 2-5µm infrared quantum-cascade type semiconductor lasers. The solution is expected to help fight cancers through targeted destruction of cells in malignant tumors. 

3D printed endoprosthesis production deal inked outside Moscow

Marchmont Innovation News

Technospark, a nanotech park in Troitsk just outside Moscow, and LVM AT, a Russian tech engineering company, have inked an agreement with Germany’s Concept Laser which is paving the way for Russia’s pioneering production of 3D printed endoprostheses for joints, interbody fusion cages and implants for intracranial and oral/maxillofacial surgery,  announced  Rusnano, Russia’s largest nanotech company. 

15 November 2016

Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data showing that the combination of its CNS-selective GABA_A modulator ganaxolone and diazepam administered intravenously (IV) produced a synergistic effect in blocking pilocarpine-induced seizures in a benzodiazepine refractory model of status epilepticus (SE). 

15 November 2016

Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 1/2 clinical trial (the “HULK” trial) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, for the treatment of diabetic macular edema (“DME”).

Pharma's Not Off the Hook for High Drug Prices

Anna Edney / Bloomberg

Even with a presumably business-friendly president-elect in Donald Trump, drugmakers that have been battered by criticism over high prices in the past year are bracing for Republican and Democratic lawmakers to take aim at the industry.

Drugmakers improve access for poo

Ben Hirschler / Reuters

The world's top drugmakers have improved access to medicines in developing countries but still need to do more to make a wider range of products affordable, according to a report on Monday.

NIH-led effort examines use of big data for infectious disease surveillance

U.S. National Institute of Health

Big data derived from electronic health records, social media, the internet and other digital sources have the potential to provide more timely and detailed information on infectious disease threats or outbreaks than traditional surveillance methods. A team of scientists led by the National Institutes of Health reviewed the growing body of research on the subject and has published its analyses in a special issue of The Journal of Infectious Diseases.

Trump, Republican victory to boost biotech M&A: Reuters

Ben Adams / Fierce Biotech

A combination of lower corporate taxes, a sense that deregulation for meds is coming and pricing issues will be dropped, bumped-up stocks and an influx of foreign cash will combine to create a perfect storm for a major biotech M&A spree, according to analysis from Reuters.

Brexit Makes Drug Agency the Most Sought After Regulator in EU

Peter Levring, Chiara Albanese / Bloomberg

The U.K. capital is home to the European Medicines Agency, which employs almost 900 people and oversees the safety of drugs sold in the European Union, a market of more than 500 million consumers. Once the U.K. splits, the EU may look to relocate it elsewhere within the 28-nation bloc.

NIH taps a trio of devicemakers for ‘artificial pancreas’ trial

Amirah Al Idrus / Fierce Medical Device

Diabetes players Dexcom and Tandem Diabetes Care are joining forces with digital health company TypeZero Technologies on a closed-loop system for blood glucose control.